Regeneron Pharmaceuticals (MEX:REGN) Other Operating Expense : MXN670 Mil (TTM As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Regeneron Pharmaceuticals Other Operating Expense?

Regeneron Pharmaceuticals's Other Operating Expense for the three months ended in Sep. 2024 was MXN158 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 was MXN670 Mil.

Regeneron Pharmaceuticals's quarterly Other Operating Expense increased from Mar. 2024 (MXN254 Mil) to Jun. 2024 (MXN267 Mil) but then declined from Jun. 2024 (MXN267 Mil) to Sep. 2024 (MXN158 Mil).

Regeneron Pharmaceuticals's annual Other Operating Expense declined from Dec. 2021 (MXN-935 Mil) to Dec. 2022 (MXN-1,753 Mil) but then increased from Dec. 2022 (MXN-1,753 Mil) to Dec. 2023 (MXN-36 Mil).

Regeneron Pharmaceuticals Other Operating Expense Historical Data

The historical data trend for Regeneron Pharmaceuticals's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Other Operating Expense Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

-3,945.51

-5,577.72

-935.44

-1,752.69

-35.65

Regeneron Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Operating Expense	Get a 7-Day Free Trial															-8.71	-8.49	253.92	267.47	157.52

Regeneron Pharmaceuticals Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN670 Mil.

Regeneron Pharmaceuticals Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MEX:REGN) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

REGN:USA 1REGN:Italy 0R2M:UK RGO:Germany RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).